On Monday, Shares of Chesapeake Energy Corporation (NYSE:CHK), lost -1.77% to $13.86, as oil prices fell more than 1 percent on Monday, retreating from the sharp rally of the previous session, on the impact of a strong dollar and worries of stubbornly high supplies as OPEC prepared to meet this week to stick to production targets.
Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas and natural gas liquids (NGL) from underground reservoirs in the United States.
Shares of General Motors Company (NYSE:GM), inclined 0.58% to $36.18, during its last trading session.
General Motors’ South Korean unit plans to expand engine output which will allow for an additional production shift, the unit’s union said - a move that may assist ease labour tensions a little as the automaker seeks to reduce costs, according to Reuters.
GM says its labour costs have risen nearly 50 percent over the past five years in South Korea, undermining the competitiveness of its Korean operations but union activists in the past have threatened ‘a war’ if output is shifted from their plants.
South Korea is one of GM’s major Asian production hubs, accounting for nearly one-fifth of its global output.
GM will start making engines used in its Equinox sport utility vehicles for export to North America starting next year, the union said. Initial plans call for output of 45,000 engines at one of its lines in Bupyeong next year, with a aim to boost production to 120,000 a year, Reuters Reports.
General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. It operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments.
At the end of Monday’s trade, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), lost -1.28% to $28.50.
Celldex Therapeutics, declared the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib (SUTENT(R)) in patients with metastatic clear cell renal cell carcinoma (CC-RCC). Varlilumab is Celldex’s fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Sunitinib is approved by the FDA as monotherapy for the treatment of advanced renal cell carcinoma (RCC), in addition to certain advanced gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. Varlilumab is presently being studied in four Phase 1/2 combination studies, and additional combination studies will be initiated in 2015.
Sunitinib blocks the function of receptor tyrosine kinases (RTKs), of which several are implicated in tumor growth, angiogenesis and metastasis. Sunitinib was selected for an investigational combination with varlilumab because it has demonstrated the potential to modulate anti-tumor immunity and reverse immune suppression in the tumor microenvironment. Varlilumab strengthens or creates an immune response against a new antigen, or target; therefore, a synergistic combination of sunitinib and varlilumab may elicit stronger responses in the immune system to fight CC-RCC and potentially other cancers. In Celldex’s Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory CC-RCC were observed, counting a durable partial response (13.0+ months) that has continued to decrease in tumor volume over time and prolonged stable disease (4 patients with a range of 5.3 to 33.0+ months).
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Finally, Celgene Corporation (NASDAQ:CELG), ended its last trade with 0.01% gain, and closed at $114.45.
Celgene Corporation, plans to present at two forthcoming investor conferences in June where Celgene administration will provide an overview of the Company.
- Tuesday, June 9, 2015, Celgene will present at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, CA at 10:20 am ET
- Wednesday, June 10, 2015, Celgene will present at the 2015 William Blair Growth Stock Conference in Chicago at 9:40 am ET
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
